Develops large-scale, clinical-grade pluripotent human embryonic stem cell lines and scalable neuron and cardiomyocyte therapy products for regenerative treatment of neurological and cardiovascular diseases. Provides PluriXcel platform technologies (defined culture and small-molecule induction) and Xcel cell therapy prototypes supplying high-quality, commercial-scale human cells to clinicians and biomanufacturers addressing unmet medical needs.